Patents by Inventor Stefan Seeber

Stefan Seeber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8268314
    Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: September 18, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
  • Publication number: 20120213774
    Abstract: An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.
    Type: Application
    Filed: February 22, 2012
    Publication date: August 23, 2012
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Georg Fertig, Jens Fischer, Guy Georges, Klaus Kaluza, Valeria Lifke, Joerg Moelleken, Sonja Offner, Achal Pashine, Stefan Seeber
  • Publication number: 20120156198
    Abstract: The invention provides anti-IL-18R1 antibodies and methods of using the same.
    Type: Application
    Filed: August 25, 2011
    Publication date: June 21, 2012
    Inventors: Michael Brandt, Jens Fischer, Stefan Jenewein, Klaus Kaluza, Eileen Samy, Stefan Seeber
  • Publication number: 20110183354
    Abstract: The present invention relates to the field of human immunoglobulin receptors, specifically the glycostructure of a human Fc gamma receptor IIIa recombinantly expressed in human embryonic kidney cells and Chinese hamster ovary cells.
    Type: Application
    Filed: March 1, 2011
    Publication date: July 28, 2011
    Inventors: ULRICH BRINKMANN, PETER BRUENKER, CLAUDIA FERRARA KOLLER, MARTIN LANZENDOERFER, JOERG THOMAS REGULA, TILMAN SCHLOTHAUER, STEFAN SEEBER, ANNE ZECK
  • Publication number: 20110165156
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: December 7, 2010
    Publication date: July 7, 2011
    Inventors: NIKOLAOS DIMOUDIS, GEORG FERTIG, ALEXANDER FIDLER, KLAUS KALUZA, MARLENE PICKL, CAROLA RIES, STEFAN SEEBER, MARTIN LANZENDOERFER, KERSTIN KRUEGER
  • Publication number: 20110086026
    Abstract: An antibody binding to IL-13R?1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of said antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9 is useful in the treatment of asthma and allergic diseases.
    Type: Application
    Filed: July 26, 2010
    Publication date: April 14, 2011
    Inventors: Josef Endl, Maria Elena Fuentes, Yvo Graus, Adelbert Grossmann, Sebastian Neumann, Paul Parren, Frank Rebers, Joerg Thomas Regula, Ralf Schumacher, Stefan Seeber, Jan Olaf Stracke, Kay-Gunnar Stubenrauch, Jan Van De Winkel, Martine Van Vugt, Sandra Vereecken-Verploegen
  • Publication number: 20110070239
    Abstract: This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.
    Type: Application
    Filed: December 1, 2010
    Publication date: March 24, 2011
    Inventors: Joseph Endl, Elsie M. Eugui, Maria Elena Fuentes, Yvo Graus, Aran Frank Labrijn, Martin Lanzendoerfer, Paul Parren, Frank Rebers, Ralf Schumacher, Stefan Seeber, Jan Van De Winkel, Martine Van Vugt
  • Patent number: 7868141
    Abstract: This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: January 11, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Joseph Endl, Elsie M. Eugui, Maria Elena Fuentes, Yvo Graus, Aran Frank Labrijn, Martin Lanzendoerfer, Paul Parren, Frank Rebers, Ralf Schumacher, Stefan Seeber, Jan Van De Winkel, Martine Van Vugt
  • Patent number: 7807158
    Abstract: The instant specification discloses an antibody binding to IL-13R?1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of this antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9, and this antibody is useful in the treatment of asthma and allergic diseases.
    Type: Grant
    Filed: January 3, 2006
    Date of Patent: October 5, 2010
    Assignee: Roche Palo Alto LLC
    Inventors: Josef Endl, Maria Elena Fuentes, Yvo Graus, Adelbert Grossmann, Sebastian Neumann, Paul Parren, Frank Rebers, Joerg Thomas Regula, Ralf Schumacher, Stefan Seeber, Jan Olaf Stracke, Kay-Gunnar Stubenrauch, Jan Van De Winkel, Martine Van Vugt, Sandra Vereecken-Verploegen
  • Patent number: 7754448
    Abstract: A method for the production of the ?-chain of hepatocyte growth factor or an N-terminal fragment thereof (NK polypeptide) by expression of a nucleic acid encoding said NK polypeptide in a microbial host cell, isolating inclusion bodies containing said NK polypeptide in denatured form, solubilization of the inclusion bodies and naturation of the denatured NK polypeptide, which is characterized in that in said nucleic acid at least one of the codons of amino acids selected from the group consisting of codons at positions 33, 35 and 36 is CGT, results in an improved expression yield.
    Type: Grant
    Filed: March 2, 2005
    Date of Patent: July 13, 2010
    Assignee: Hoffman-La Roche Inc.
    Inventors: Johannes Auer, Apollon Papadimitriou, Christian Schantz, Stefan Seeber
  • Publication number: 20100166740
    Abstract: This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.
    Type: Application
    Filed: December 5, 2008
    Publication date: July 1, 2010
    Inventors: Joseph Endl, Elsie M. Eugui, Maria Elena Fuentes, Yvo Graus, Aran Frank Labrijn, Martin Lanzendoerfer, Paul Parren, Frank Rebers, Ralf Schumacher, Stefan Seeber, Jan Van de Winkel, Martine Van Vugt
  • Publication number: 20100111967
    Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: October 2, 2009
    Publication date: May 6, 2010
    Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
  • Patent number: 7615216
    Abstract: Antibodies that specifically bind to CCR5 are useful for treating immunosuppressive disease.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: November 10, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Michael Brandt, Surya Sankuratri, Ralf Schumacher, Stefan Seeber
  • Patent number: 7541163
    Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.
    Type: Grant
    Filed: August 14, 2007
    Date of Patent: June 2, 2009
    Assignees: Maxygen, Inc., Roche Palo Alto LLC
    Inventors: Phillip A. Patten, Sridhar Viswanathan, Torben Lauesgaard Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse
  • Patent number: 7541436
    Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.
    Type: Grant
    Filed: May 4, 2007
    Date of Patent: June 2, 2009
    Assignees: Maxygen, Inc., Roche Palo Alto LLC
    Inventors: Phillip A. Patten, Sridhar Viswanathan, Torben Lauesgaard Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Andreas Schaubmar, Hans Koll
  • Patent number: 7537755
    Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.
    Type: Grant
    Filed: August 15, 2007
    Date of Patent: May 26, 2009
    Assignees: Maxygen, Inc., Roche Palo Alto LLC
    Inventors: Phillip A. Patten, Sridhar Viswanathan, Torben Lauesgaard Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Andreas Schaubmar, Hans Koll
  • Patent number: 7531324
    Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.
    Type: Grant
    Filed: September 13, 2006
    Date of Patent: May 12, 2009
    Assignee: Maxygen, Inc.
    Inventors: Phillip A. Patten, Sridhar Viswanathan, Torben Lauesgaard Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Andreas Schaubmar, Roberto Falkenstein
  • Patent number: 7531630
    Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.
    Type: Grant
    Filed: September 13, 2006
    Date of Patent: May 12, 2009
    Assignee: Maxygen, Inc.
    Inventors: Phillip A. Patten, Sridhar Viswanathan, Torben Lauesgaard Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Andreas Schaubmar, Hans Koll
  • Patent number: 7501496
    Abstract: This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.
    Type: Grant
    Filed: September 16, 2005
    Date of Patent: March 10, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Joseph Endl, Elsie M. Eugui, Maria Elena Fuentes, Yvo Graus, Aran Frank Labrijn, Martin Lanzendoerfer, Paul Parren, Frank Rebers, Ralf Schumacher, Stefan Seeber, Jan Van De Winkel, Martine Van Vugt
  • Publication number: 20080248510
    Abstract: The present invention relates to the field of human immunoglobulin receptors, specifically the glycostructure of a human Fc gamma receptor IIIa recombinantly expressed in human embryonic kidney cells and Chinese hamster ovary cells.
    Type: Application
    Filed: March 27, 2008
    Publication date: October 9, 2008
    Inventors: Ulrich Brinkmann, Peter Bruenker, Claudia Ferrara Koller, Martin Lanzendoerfer, Joerg Thomas Regula, Tilman Schlothauer, Stefan Seeber, Anne Zeck